Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Amphastar Pharmaceuticals Inc (AMPH) vs iShares Broad USD Investment Grade Corporate Bond (USIG) Price & Performance

Amphastar Pharmaceuticals IncTrade
iShares Broad USD Investment Grade Corporate BondTrade

Price performance (Past 24H)

Key statistics

Amphastar Pharmaceuticals Inc vs iShares Broad USD Investment Grade Corporate Bond — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while iShares Broad USD Investment Grade Corporate Bond trades at $50.2. The key difference: Amphastar Pharmaceuticals Inc is trading nearer its 52-week high, iShares Broad USD Investment Grade Corporate Bond nearer its low. Which is the better fit depends on your goals.

AMPHUSIG
Market Cap
$863.95M
Sector
HealthFixed Income
52-Week High
$30.81$52.69
52-Week Low
$16.87$50.18
Enterprise Value
$1.26B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Amphastar Pharmaceuticals Inc

AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.

Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.

iShares Broad USD Investment Grade Corporate Bond

USIG trades at $50.40 with minimal daily movement (+0.16%). Technical indicators show a bearish bias with moving averages signaling caution, though oscillators remain neutral. The company maintains consistent dividend distributions, with recent payouts of $0.20-$0.21 per share. Recent news includes AM Best affirming credit ratings for subsidiaries following a transaction with Tiptree Inc.

Investment outlook remains cautious given bearish technical signals and limited fundamental data availability. The steady dividend history provides income appeal, but investors face uncertainty from incomplete financial metrics. Key risks include potential volatility from institutional positioning changes and transaction integration challenges with Tiptree.

Returns comparison

Trailing returns across standard periods

About Amphastar Pharmaceuticals Inc

Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.

Read more on AMPH

About iShares Broad USD Investment Grade Corporate Bond

USIG is a low-cost ETF providing broad exposure to over 11,000 U.S. investment-grade corporate bonds. It tracks the ICE BofA US Corporate Index, featuring high-quality debt from 2026 leaders like Citigroup, Bank of America, and Oracle.

Read more on USIG